31 human secreted proteins

摘要

Human secreted polynucleotides and the proteins they encode are new. Independent claims are included for the following: (1) an isolated nucleic acid molecule (I) comprising a polynucleotide with a nucleotide sequence at least 95% identical to one of the following sequences: (a) a polynucleotide fragment of one of 31 defined gene sequences (A) given in the specification or a polynucleotide fragment of the cDNA sequence included in one of 31 ATCC deposits (C) which is hybridizable to (A); (b) a polynucleotide encoding a polypeptide fragment of one of 31 defined sequences (B) given in the specification or a polynucleotide fragment of (C); (c) a polynucleotide encoding a polypeptide domain of (B) or a polypeptide domain encoded by (C); (d) a polynucleotide encoding a polypeptide epitope of (B) or a polypeptide epitope encoded by (C); (e) a polynucleotide encoding a polypeptide of (B) or the cDNA sequence included in (C), having biological activity; (f) a polynucleotide which is a variant of (A); (g) a polynucleotide which is an allelic variant of (A); (h) a polynucleotide which encodes a species homologue of (B); or (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides of (a)-(h) but does not hybridize to a nucleic acid molecule with a nucleotide sequence of only A or T residues; (2) a recombinant vector comprising (I); (3) a method of preparing a recombinant host cell comprising (I); (4) a recombinant host cell produced by the method of (3); (5) an isolated polypeptide (II) comprising an amino acid sequence at least 95% identical to one of the following sequences: (a) a polypeptide fragment of (B) or the encoded sequence included in (C); (b) a polypeptide fragment of (B) or the encoded sequence included in (C) with biological activity; (c) a polypeptide epitope of (B) or the encoded sequence included in (C); (d) a secreted form of (B) or the encoded sequence included in (C); (e) a full length protein of (B) or the encoded sequence included in (C); (f) a variant of (B); (g) an allelic variant of (B); or (h) a species homologue of (B); (6) an isolated antibody that binds specifically to (II); (7) a recombinant host cell that expresses (II); (8) a method of making (II) comprising culturing the recombinant host cell of (7) under conditions so that the polypeptide is expressed and recovering the polypeptide; (9) a method for diagnosing a pathological condition or susceptibility to a pathological condition in a subject comprising determining the presence or absence of a mutation in (I) and making a diagnosis based on the presence or absence of the mutation; (10) a method for diagnosing a pathological condition or susceptibility to a pathological condition in a subject comprising determining the presence or amount of expression of (II) in a biological sample and making a diagnosis based on the presence or amount of expression of the protein; (11) a method of identifying a binding partner to (II) comprising contacting (II) with a binding partner and determining any effect on the activity of (II); (12) the gene corresponding to the cDNA sequence of (C); (13) a method of identifying an activity in a biological assay comprising expressing (A) in a host cell, isolating the supernatant, detecting an activity in a biological assay and identifying the protein in the supernatant with the activity; and (14) the product identified by the method of (13). ACTIVITY : Cytostatic; Proliferative; Antiallergic; Dermatological; Immunosuppressive; Antiarrhythmic; Cardiant; Vulnerary; Antibacterial; Virucide. Human umbilical vein endothelial cells (HUVEC) were seeded at 2-5 x 10 4>cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin and 50 units/ml endothelial cell growth supplements. The following day the medium was replaced with M199 containing 10% FBS and 8 units/ml heparin. A polypeptide with amino acid sequence (B) and positive controls e.g. basic fibroblast growth factor (bFGF) were added at various concentrations. The medium was replaced on days 4 and 6 and on day 8 cell number was determined with a Coulter counter. An increase in the number of HUVEC cells would indicate the polypeptide of the invention proliferates vascular endothelial cells. No results are given. MECHANISM OF ACTION : Gene therapy.